SCHEMBL752896

SCHEMBL752896

C[C@H](c1ccc(OCc2ccc(C(=O)O)cc2)cc1Cl)[C@@](O)(c1ccnc(Cl)c1)C(F)(F)F

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RXRA P19793 7/20 0.45
RXRB P28702 7/20 0.45
NR4A2 P43354 5/20 0.43
MRGPRX4 Q96LA9 2/20 0.43
RXRG P48443 3/20 0.42
FFAR1 O14842 1/20 0.41
NR1H4 Q96RI1 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
LIFR P42702 2/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP26A1 O43174 1/20 0.39
CYP3A4 P08684 1/20 0.39
NR4A1 P22736 1/20 0.38
NR4A3 Q92570 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL479802 1.00 RXRA (0.45) RXRARXRBNR4A2MRGPRX4RXRG
SCHEMBL479611 0.92 RXRA (0.44) RXRARXRBNR4A2MRGPRX4RXRG
SCHEMBL479814 0.92 FFAR1 (0.42) RXRARXRBMRGPRX4RXRGFFAR1
SCHEMBL753142 0.92 FFAR1 (0.42) RXRARXRBMRGPRX4RXRGFFAR1
SCHEMBL480006 0.92 RXRA (0.47) RXRARXRBNR4A2MRGPRX4RXRG
SCHEMBL754732 0.91 MAOB (0.45) RXRARXRBFFAR1SMN1; SMN2
SCHEMBL480004 0.91 MAOB (0.45) RXRARXRBFFAR1SMN1; SMN2
SCHEMBL479858 0.90 MRGPRX4 (0.36) RXRARXRBNR4A2MRGPRX4FFAR1
SCHEMBL479786 0.89 PTGER4 (0.39) RXRARXRBRXRGNPC1RAB9A
SCHEMBL753140 0.89 NPC1 (0.45) MRGPRX4FFAR1NR1H4NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-8138189-B2 Substituted benzene compounds as modulators of the glucocorticoid receptor HOFFMAN-LA ROCHE INC. (US) 2012-03-20 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS HOFFMANN-LA ROCHE, INC. 2010-09-30 US disclosed
WO-2010108902-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249139-A1 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS NR3C1, NR3C2, CRHR1 RXRA 584/4885RXRB 917/4885NR4A2 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.